Jilin Maifeng

Jilin Maifeng Biopharmaceutical is a Chinese biotechnology company specializing in the development and manufacture of human vaccines, primarily focusing on rabies prevention. As a subsidiary of Changchun BCHT Biotechnology, the company utilizes advanced large-scale bioreactor and microcarrier cell culture technologies to produce its flagship product, the Human Rabies Vaccine (Vero Cell). The company's manufacturing facilities are designed to meet international standards, ensuring the production of high-purity and high-potency biological products. Jilin Maifeng plays a critical role in the Chinese public health sector by providing essential immunization solutions for infectious diseases. Its operations are integrated into the broader vaccine portfolio of its parent company, contributing to a comprehensive range of preventive healthcare products.